REG - Theracryf PLC - Issue of Equity and Total Voting Rights

TheracryfAnnouncement

14/11/2024 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241114:nRSN3178Ma&default-theme=true

RNS Number : 3178M  Theracryf PLC  14 November 2024

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

Alderley Park, UK - 14 Nov 2024: TheraCryf plc (AIM: TCF), the clinical stage
drug development company focussing on oncology and neuropsychiatry, announces
that the Company has issued 2,275,527 new ordinary shares of 0.25 pence each
in the capital of the Company ("Ordinary Shares") in lieu of professional
fees.

Application will be made for 2,275,527 Ordinary Shares to be admitted to
trading on AIM ("Admission"). Admission is expected to occur on or around 20
November 2024 and the Ordinary Shares will, on issue, rank pari passu in all
respects with the Company's existing Ordinary Shares.

On Admission, the Company will have a total of 429,622,422 Ordinary Shares in
issue. No Ordinary Shares are held in treasury. The figure of 429,622,422 may
be used by the Company's shareholders as the denominator in the calculations
by which they will determine if they are required to notify their interest in,
or a change to their interest in, the Company under the Financial Conduct
Authority's Disclosure, Guidance and Transparency Rules.

 

-Ends-

Enquiries

 TheraCryf plc                                               +44 (0)1625 315 090

Dr Huw Jones, CEO
enquiries@theracryf.com

Toni Hänninen, CFO

Dr Helen Kuhlman, CBO
 Cavendish Capital Markets (NOMAD and Broker)                +44 20 7220 0500
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)

Nigel Birks / Harriet Ward (ECM)
 Vigo Consulting                                             +44 207 7390 0230
 Rozi Morris
theracryf@vigoconsulting.com

 

About TheraCryf

TheraCryf is a clinical stage drug development company focussing on oncology
and neuropsychiatry. The Company has a broad clinical and preclinical pipeline
in indications including glioblastoma*, neurodevelopmental disorders,
addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or
clinical proof of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation, including Stalicla SA,
in neurodevelopmental disorders. The Company has sourced know how for
programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol TCF. 

For further information, please visit: www.theracryf.com
(file:///C:/Users/MToyneSewell/AppData/Local/Microsoft/Windows/INetCache/Content.Outlook/XN44CN5I/www.theracryf.com)
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEQKQBBPBDDBDD